CAMBRIDGE, Mass. & SALISBURY, England - KalVista Pharmaceuticals, Inc. (NASDAQ: NASDAQ:KALV) has received Orphan Drug ...

KalVista (KALV) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has granted sebetralstat orphan drug designation. The ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has ...

Bank of America on Wednesday launched its coverage of KalVista Pharmaceuticals (NASDAQ:KALV) with a Buy recommendation, citing a broad uptake for the company’s lead candidate, sebetralstat.

KalVista Pharmaceuticals Inc. submitted a new drug application to the FDA for the approval of sebetralstat for patients aged 12 years and older with hereditary angioedema (HAE). Sebetralstat is ...

Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P.

KalVista Pharmaceuticals, Inc. (KALV) announced Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted ...